PMC10285519_01
Five month-follow up of HBV DNA and liver function parameters: while HBV DNA decreased after Tenofovir, no signs of toxicity occurred after combination of Ribociclib + ET + Tenofovir.
fonc-13-1184952-g001.jpg
PMC10285519_01_fonc-13-1184952-g001.jpg
f1
(A) CT scan showing thickened right mammal gland. (B) Revaluation CT scan showing reduced mass in infero-external right breast.
fonc-13-1184952-g002.jpg
PMC10285519_01_fonc-13-1184952-g002.jpg
f2
After three cycles of treatment with Ribociclib, in January 2022, 18FDG PET plus contrast-enhanced CT and breast MRI were repeated ( Figure 2 ).
(A) Breast MRI of September 2021: multiple lesions occupying an area of 90x33x60mm in the right breast, below, 18-FDG PET scan of September 2021 showing contrast enhancement in right breast (B). (C) Breast MRI of January 2022: subcutaneous nodules at infero-external and infero-internal right quadrants, with no 18- FDG uptake (see below, D). (E) Breast MRI of May 2022: subcutaneous nodules at infero- external and infero-internal right quadrants, with no 18-FDG uptake (see below, F).
fonc-13-1184952-g003.jpg
PMC10285519_01_fonc-13-1184952-g003.jpg
f3
Timeline with most relevant case episodes.
fonc-13-1184952-g004.jpg
PMC10285519_01_fonc-13-1184952-g004.jpg
f4
Moreover, despite undergoing such an intense treatment, patient's mood was constantly good; she did not ask or manifest need of psychological support and, to the date, patient shows a positive thinking and feelings of gratitude ( Figure 4 ).